Media Release

Cordlife launches NICE®, a clinically approved non-invasive prenatal test in Indonesia and Philippines

- Cordlife is partnering with Eone-Diagnomics Genome Center (EDGC), an internationally certified laboratory in South Korea, to offer NICE® non-invasive prenatal testing in Indonesia and the Philippines.

- NICE® can detect chromosomal abnormalities in pregnancies as early as week 10 with over 99% accuracy.

- EDGC will use next generation sequencing technology along with their NICE® proprietary algorithms delivered through a clinically approved cloud-computing platform to detect up to 10 foetal chromosomal aneuploidies from cell-free DNA found in maternal blood.

SINGAPORE, 13 December 2017 – Cordlife Group Limited (“Cordlife”), a consumer healthcare company listed on the mainboard of Singapore Exchange, today announced the official launch of NICE® (Non-Invasive Chromosome Examination), a new clinically approved non-invasive prenatal test (“NIPT”) in Indonesia and the Philippines. A proprietary test of South Korean based company Eone-Diagnomics Genome Center (“EDGC”), NICE® can detect up to 10 chromosomal abnormalities with high accuracy without putting the expectant mother and preborn child at risk.

NICE® will be marketed under Genscreen®, a brand of Cordlife. The service is available through most obstetricians in Indonesia and the Philippines. For more information, please visit www.genscreen.asia/nice.

### End ###

Media & Investor Contact Information
WeR1 Consultants Pte Ltd
3 Phillip Street, #12-01, Royal Group Building
Singapore 048693
Tel: (65) 6737 4944
Frankie Ho – frankieho@wer1.net
Grace Yew – graceyew@wer1.net
Afina Kong – afinakong@wer1.net
ABOUT CORDLIFE GROUP LIMITED
(Bloomberg: CLGL; Reuters: CORD.SI)

Incorporated in May 2001, Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”) is a leading provider of cord blood, cord tissue and umbilical cord lining banking services in Asia.

As a consumer healthcare company catering to the mother and child segment, Cordlife has the largest market share among private cord blood banks in Singapore, the Philippines and Indonesia as well as among the top 3 market leaders in Hong Kong and India. In February 2017, Cordlife increased its shareholding in Stemlife Berhad, the largest cord blood bank in Malaysia and the latest addition to the subsidiaries of the Group, to 99.03%. Cordlife is also the first Singapore private cord blood bank in Myanmar and Vietnam.

Quality-wise, the Group’s in-depth knowledge on stem cell banking practices and standards have been recognised by many international quality standard organisations. Their facility in Singapore is one of only six private cord blood banks in the world to be dually accredited by AABB and FACT, two of the world’s gold standards for cord blood banking. The Group’s processing and storage facilities in Hong Kong, India and the Philippines are also accredited by AABB, while their facilities in Indonesia and Malaysia are ISO-certified. Their cord blood banking facility in India and metabolic screening laboratory in Hong Kong are accredited by the College of American Pathologists (“CAP”), a world-class standard, which recognises facilities that meet or exceed the highest standards in clinical laboratory services.

Cordlife has been listed on the mainboard of Singapore Exchange since March 2012. For more information, visit http://cordlife.listedcompany.com